The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study

CONCLUSION: In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.PMID:38043782 | PMC:PMC10695717 | DOI:10.4093/dmj.2023.0171

Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Jun Sung Moon Il Rae Park Sang Soo Kim Hye Soon Kim Nam Hoon Kim Sin Gon Kim Seung Hyun Ko Ji Hyun Lee Inkyu Lee Bo Kyeong Lee Kyu Chang Won Source Type: research